Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. J. Pharm. Sci. (Online) ; 59: e21461, 2023. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1429963

RESUMO

Abstract he innate immune response plays an important role in the pathophysiology of acute respiratory distress syndrome (ARDS); however, no drug has been proven to be beneficial in the management of ARDS. Therefore, the aim of this study was to investigate the effects of using combined sedatives on systemic inflammatory responses in patients with ARDS. A total of 90 patients with ARDS and an intubation time of > 120 h were randomly divided into the propofol group (group P), midazolam group (group M), and combined sedation group (group U). Patients in groups P and M were sedated with propofol and midazolam, respectively, whereas patients in group U were sedated with a combination of propofol, midazolam, and dexmedetomidine. The dosage of sedatives and vasoactive drugs, duration of mechanical ventilation, and incidence of sedative adverse reactions were documented. The dosage of sedatives and vasoactive drugs, as well as the incidence of sedative adverse reactions in group U, was significantly lower than those in groups P and M. Similarly, the duration of mechanical ventilation in group U was significantly shorter than that in groups P and M. Hence, inducing sedation through a combination of multiple drugs can significantly reduce their adverse effects, improve their sedative effect, inhibit systemic inflammatory responses, and improve oxygenation in patients with ARDS


Assuntos
Humanos , Masculino , Feminino , Adulto , Pacientes/classificação , Síndrome do Desconforto Respiratório do Recém-Nascido/diagnóstico , Preparações Farmacêuticas/análise , Sedação Consciente/efeitos adversos , Midazolam/agonistas , Propofol/agonistas , Citocinas/administração & dosagem , Dexmedetomidina/agonistas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA